Clinical Significance of Quantitative HBs Antigen in the Prediction of Liver Fibrosis in Patients with Chronic Hepatitis B

1. Kao JH, Chen DS.“Global control of hepatitis B virus infection”. Lancet Infect Dis. 2002; 2: 395.10.1016/S1473-3099(02)00315-8Open DOISearch in Google Scholar

2. http://www.who.int/mediacenter/factsheets/fs204/en/Search in Google Scholar

3. Lavanchy D. “Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.” J. Viral Hepat. 2004; 11: 97–107.10.1046/j.1365-2893.2003.00487.xSearch in Google Scholar

4. Bedossa P, Carrat F.“Liver biopsy: the best, not the gold standard. J Hepatol. 2009; 50: 1-3.10.1016/j.jhep.2008.10.01419017551Open DOISearch in Google Scholar

5. Xu X, Su Y, Song R et all: “Performance of transient elastography assessing fibrosis of single hepatitis B infection: A systematic review and meta-analysis of a diagnostic test.” Hepatol Int. 2015; 9: 558-6610.1007/s12072-015-9643-z26187292Search in Google Scholar

6. Gheorghița V. et al.“Quantitative serum HBsAg in chronic hepatitis B.” Therapeutics, Pharmacology and Clinical Toxicology. 2012; 16 (3): 155-162.Search in Google Scholar

7. LiawYF. “Clinical Utility of Hepatitis B surface Antigen Quantitation in Patients with Chronic Hepatitis B: A Review.” Hepatology. 2011; 53: 2121-2129.10.1002/hep.2436421503943Search in Google Scholar

8. Chevaliez S: “Is HBsAg quantification ready for prime time?” Clin Res Hepatolo Gastroenterol. 2013; 37: 559-63.10.1016/j.clinre.2013.07.00423932705Search in Google Scholar

9. Loggi E, Vitale G., Conti F., Bernardi M. “Chronic hepatitis B: Are we close to a cure?” Digestive and Liver Disease. 2015; 47: 836-841.10.1016/j.dld.2015.05.019Search in Google Scholar

10. Martinot-PeginouxM et al.: HBsAg quantification to predict natural history and treatment outcome in chronic hepatitis B patients. Clin Liver Dis. 2013, 17: 399-412.10.1016/j.cld.2013.05.00623905812Search in Google Scholar

11. Samant H, Joshi Aet al. “Correlation of QuantitativeHBsAg with Quantitative HBV DNA in Different Phases of Chronic Hepatitis B (CHB) Patients.”J Liver Res Disord Ther. 2016; 1(3).10.15406/jlrdt.2016.01.00014Search in Google Scholar

12. Thompson AJ, Nguyen T, Iser D, et al. “Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers.” Hepatology. 2010; 51: 1933–1944.10.1002/hep.2357120512987Open DOISearch in Google Scholar

13. Brunetto MR. “A new role for an old marker, HBsAg.” J Hepatol. 2010; 52: 475-477.10.1016/j.jhep.2009.12.02020185190Open DOISearch in Google Scholar

14. European Association for the Study of the Liver. EASL clinical practice guidelines: “Management of chronic hepatitis B virus infection.” J Hepatol. 2017; 67: 370–398.Search in Google Scholar

15. Seto WK, Wong DK et al. “High hepatitis B surface antigen levels predict insignigicant fibrosis in hepatitis B e antigen positive chronic hepatitis B.” PLoS One. 2012; 7: e4308710.1371/journal.pone.0043087342344022916211Search in Google Scholar

16. Zhu HY, Zhang XS. “Relationship between HBV DNA load and levels of serum HBsAg in patients with chronic hepatitis B.” European Review for Medical and Pharmacological Sciences. 2016; 20: 2061-2064.Search in Google Scholar

17. Balkan A., Namiduru M.et al. “Are Serum Quantitavie Hepatitis B surface Antigen Levels, Liver Histopathology and Viral Loads related in Chronic Hepatitis B-Infected Patients?” Saudi J Gastronterol. 2016; 22(3) 208-214.10.4103/1319-3767.182454489809027184639Search in Google Scholar

18. Hong MZ, Huagn WQ et al. “Enhanced HBsAg synthesis correlates with increased severity of fibrosis in chronic hepatitis B patients.” PLoS One. 2014; 9: 1:e87344.10.1371/journal.pone.0087344390909924498079Search in Google Scholar

19. Günal et al. “Relation between serum quantitative HBsAg, ALT and HBV DNAlevels in HBeAg negative chronic HBV infection.” Turk J Gastroenterol. 2014; 25: 142-6.10.5152/tjg.2014.571125910293Search in Google Scholar

20. Liu J, Yang H, Lee M.,2 Jen C,1 Utermann R., Lu S.et all. “Serum Levels of Hepatitis B SurfaceAntigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression.” Hepatology. 2016; 64: 381-389.10.1002/hep.2855227079545Search in Google Scholar